GTBP · NASDAQ
GT Biopharma (GTBP) Stock Price & Fundamentals
GT Biopharma (GTBP) closed at $728.12 on Oct 9, 2026, down 0.11% from the previous close of $728.89.
Share price, past year
1Y +32.37%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $728.12 |
| Sep 30, 2026 | $710.62 |
| Aug 31, 2026 | $721.63 |
| Jul 31, 2026 | $731.27 |
| Jun 30, 2026 | $727.82 |
| May 29, 2026 | $649.59 |
| Apr 30, 2026 | $656.52 |
| Mar 31, 2026 | $649.59 |
| Feb 27, 2026 | $571.60 |
| Jan 30, 2026 | $520.53 |
| Dec 31, 2025 | $557.84 |
| Nov 28, 2025 | $545.55 |
| Oct 31, 2025 | $531.21 |
Key statistics
- Market cap
- $32.52B
- P/E (TTM)
- 167.8
- EPS (TTM)
- $4.34
- Revenue (TTM)
- —
- Net income (TTM)
- −$4.76M
- Shares outstanding
- 44.7M
- Dividend yield
- —
- 52-week range
- $516.13 – $745.40
GT Biopharma's market cap is $32.52B, based on a share price of $728.12 and 44.7M shares outstanding as of Jun 30, 2026.
Financials
GT Biopharma reported revenue of $0.00 for fiscal 2020.
GT Biopharma reported a net loss of $28.35M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2020ended Dec 31, 2020 | $0.00 | — | −$28.30M | — | −$6.45 | — |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$38.65M | — | −$0.01 | −$3.66M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$144.17M | — | −$8.60 | −$5.43M |
| FY2016ended Dec 31, 2016 | $0.00 | −100.0% | $9.77M | — | $119.91 | −$1.93M |
| FY2015ended Dec 31, 2015 | $27.00K | −55.7% | — | — | — | −$4.66M |
| FY2014ended Dec 31, 2014 | $61.00K | −83.4% | — | — | — | −$1.76M |
| FY2013ended Dec 31, 2013 | $368.00K | +7.6% | — | — | — | −$442.00K |
| FY2012ended Dec 31, 2012 | $342.00K | +1,215.4% | — | — | — | −$989.00K |
| FY2011ended Dec 31, 2011 | $26.00K | +136.4% | — | — | — | −$963.00K |
| FY2010ended Dec 31, 2010 | $11.00K | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2021ended Sep 30, 2021 | $0.00 | — | — |
| Q2 FY2021ended Jun 30, 2021 | $0.00 | — | — |
| Q1 FY2021ended Mar 31, 2021 | $0.00 | — | — |
| Q4 FY2020ended Dec 31, 2020 | $0.00 | — | — |
| Q3 FY2020ended Sep 30, 2020 | $0.00 | — | — |
| Q2 FY2020ended Jun 30, 2020 | $0.00 | — | — |
| Q1 FY2020ended Mar 31, 2020 | $0.00 | — | — |
| Q1 FY2019ended Mar 31, 2019 | $0.00 | — | — |
Company profile
- Name
- GT Biopharma, Inc.
- Ticker
- GTBP
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 505 Montgomery Street, 10th Floor, San Francisco, CA 94111
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000109657
Recent SEC filings
- Sep 25, 2026
- Sep 21, 2026
- Sep 15, 2026
- Sep 3, 2026
- Aug 14, 2026
- Aug 14, 2026
- Jun 12, 2026
- May 22, 2026
Frequently asked questions
What is GT Biopharma's stock price?
GT Biopharma (GTBP) closed at $728.12 on Oct 9, 2026, down 0.11% from the previous close of $728.89.
What is GT Biopharma's market cap?
GT Biopharma's market cap is $32.52B, based on a share price of $728.12 and 44.7M shares outstanding as of Jun 30, 2026.
How much revenue does GT Biopharma make?
GT Biopharma reported revenue of $0.00 for fiscal 2020.
What is GTBP's P/E ratio?
GT Biopharma's price-to-earnings ratio is 167.8, based on trailing twelve-month diluted EPS of $4.34.
Does GT Biopharma pay a dividend?
GT Biopharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from GT Biopharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures